<sup>64</sup>Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

Hicks, Rodney J.; Jackson, Price; Kong, Grace; Ware, Robert E.; Hofman, Michael S; Pattison, David A.; Akhurst, Timothy; Drummond, Elizabeth; Roselt, Peter; Callahan, Jason; Price, Roger I.; Jeffery, Charmaine M.; Hong, Emily; Noonan, Wayne; Herschtal, Alan; Hicks, Lauren; Hedt, Amos; Harris, Matthew J; Paterson, Brett M.; Donnelly, Paul S.

doi:10.2967/jnumed.118.217745

Cited by 110 publications

(74 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a complete image-based dosimetry tool, the algorithm has been employed in a variety of clinical studies for both therapeutic and diagnostic dose evaluation which have been used to inform patient management. [24][25][26][27] The overall residual error was observed to be comparable between iteratively optimized and tri-exponential algorithms, however, the VoMM method was shown to be most accurate at the early image phase with increasing error at later time points. This is to be anticipated as the observed activityand potential to influence sum of squared errorcarries less weight for the optimization task.…”

Section: Resultsmentioning

confidence: 99%

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Dosimetry in nuclear medicine often relies on estimating pharmacokinetics based on sparse temporal data. As analysis methods move toward image-based three-dimensional computation, it becomes important to interpolate and extrapolate these data without requiring manual intervention; that is, in a manner that is highly efficient and reproducible. Iterative least-squares solvers are poorly suited to this task because of the computational overhead and potential to optimize to local minima without applying tight constraints at the outset. Methodology: This work describes a fully analytical method for solving three-phase exponential time-activity curves based on three measured time points in a manner that may be readily employed by image-based dosimetry tools. The methodology uses a series of conditional statements and a piecewise approach for solving exponential slope directly through measured values in most instances. The proposed algorithm is tested against a purpose-designed iterative fitting technique and linear piecewise method followed by single exponential in a cohort of ten patients receiving 177 Lu-DOTA-Octreotate therapy. Results: Tri-exponential time-integrated values are shown to be comparable to previously published methods with an average difference between organs when computed at the voxel level of 9.8 AE 14.2% and À3.6 AE 10.4% compared to iterative and interpolated methods, respectively. Of the three methods, the proposed tri-exponential algorithm was most consistent when regional time-integrated activity was evaluated at both voxel-and whole-organ levels. For whole-body SPECT imaging, it is possible to compute 3D time-integrated activity maps in <5 min processing time. Furthermore, the technique is able to predictably and reproducibly handle artefactual measurements due to noise or spatial misalignment over multiple image times. Conclusions: An efficient, analytical algorithm for solving multiphase exponential pharmacokinetics is reported. The method may be readily incorporated into voxel-dose routines by combining with widely available image registration and radiation transport tools.

show abstract

Section: Resultsmentioning

confidence: 99%

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…A first-in-human retrospective study was recently conducted and seems to present same results than [ 64 Cu]-DOTATATE with high detection rate of suspected lesion associated to a high target-to-background contrast [ 123 ]. A recent first-in-human study also demonstrated potential interest for [ 64 Cu]-SARTATE analog [ 124 ].…”

Section: Targeting Of Somatostatin Receptors With Radiopharmaceutimentioning

confidence: 99%

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

et al. 2020

View full text Add to dashboard Cite

Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads to the internalization of the ligand–receptor complex and triggers different cellular signaling pathways. Interestingly, the expression of SSTRs is significantly enhanced in many solid tumors, especially gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). Thus, somatostatin analogs (SSAs) have been developed to improve the stability of the endogenous ligand and so extend its half-life. Radiolabeled analogs have been developed with several radioelements such as indium-111, technetium-99 m, and recently gallium-68, fluorine-18, and copper-64, to visualize the distribution of receptor overexpression in tumors. Internal metabolic radiotherapy is also used as a therapeutic strategy (e.g., using yttrium-90, lutetium-177, and actinium-225). With some radiopharmaceuticals now used in clinical practice, somatostatin analogs developed for imaging and therapy are an example of the concept of personalized medicine with a theranostic approach. Here, we review the development of these analogs, from the well-established and authorized ones to the most recently developed radiotracers, which have better pharmacokinetic properties and demonstrate increased efficacy and safety, as well as the search for new clinical indications.

show abstract

“…The somatostatin receptor analogs are used to direct radionuclides for uptake by tumor cells, leading to death in a targeted fashion. Preliminary data using copper-64 labeled SARTATE suggests it can be safe and effective in neuroendocrine tumors (89). This radionuclide, and others including 177Lu-DOTA-Tyr3octreotate (Lutathera), are currently in trials for meningioma (NCT03936426, NCT03971461).…”

Section: Novel Approachesmentioning

confidence: 99%

Recent Advances in Meningioma Immunogenetics

2020

View full text Add to dashboard Cite

Meningiomas are relatively common, and typically benign intracranial tumors, which in many cases can be cured by surgical resection. However, less prevalent, high grade meningiomas, grow quickly, and recur frequently despite treatment, leading to poor patient outcomes. Across tumor grades, subjective guidelines for histological analysis can preclude accurate diagnosis, and an insufficient understanding of recurrence risk can cloud the choice of optimal treatment. Improved diagnostic and prognostic markers capable of discerning between the 15 heterogeneous WHO recognized meningioma subtypes are necessary to improve disease management and identify new targeted drug treatments. In this review, we show the advances in molecular profiling and immunophenotyping of meningiomas, which may lead to the development of new personalized therapeutic strategies.

show abstract

⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

Abstract: http://jnm.snmjournals.org/content/60/6/777 This article and updated information are available at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Cited by 110 publications

References 23 publications

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

Recent Advances in Meningioma Immunogenetics

Contact Info

Product

Resources

About

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

Abstract: http://jnm.snmjournals.org/content/60/6/777 This article and updated information are available at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/misc/permission.xhtml

Cited by 110 publications

References 23 publications

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

Technical Note: Rapid multiexponential curve fitting algorithm for voxel‐based targeted radionuclide dosimetry

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy

Recent Advances in Meningioma Immunogenetics

Contact Info

Product

Resources

About

⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy